These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 28048940)

  • 41. A site-directed mutagenesis study of the MdmX RING domain.
    Egorova O; Mis M; Sheng Y
    Biochem Biophys Res Commun; 2014 May; 447(4):696-701. PubMed ID: 24755078
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparative study of the p53-mdm2 and p53-MDMX interfaces.
    Böttger V; Böttger A; Garcia-Echeverria C; Ramos YF; van der Eb AJ; Jochemsen AG; Lane DP
    Oncogene; 1999 Jan; 18(1):189-99. PubMed ID: 9926934
    [TBL] [Abstract][Full Text] [Related]  

  • 43. MDM2/MDMX inhibitor peptide: WO2008106507.
    Macchiarulo A; Pellicciari R
    Expert Opin Ther Pat; 2009 May; 19(5):721-6. PubMed ID: 19441944
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Isolation and identification of the human homolog of a new p53-binding protein, Mdmx.
    Shvarts A; Bazuine M; Dekker P; Ramos YF; Steegenga WT; Merckx G; van Ham RC; van der Houven van Oordt W; van der Eb AJ; Jochemsen AG
    Genomics; 1997 Jul; 43(1):34-42. PubMed ID: 9226370
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Probing the alpha-helical structural stability of stapled p53 peptides: molecular dynamics simulations and analysis.
    Guo Z; Mohanty U; Noehre J; Sawyer TK; Sherman W; Krilov G
    Chem Biol Drug Des; 2010 Apr; 75(4):348-59. PubMed ID: 20331649
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Targeting protein-protein interactions: lessons from p53/MDM2.
    Murray JK; Gellman SH
    Biopolymers; 2007; 88(5):657-86. PubMed ID: 17427181
    [TBL] [Abstract][Full Text] [Related]  

  • 47. MDMX inhibits the p300/CBP-mediated acetylation of p53.
    Sabbatini P; McCormick F
    DNA Cell Biol; 2002 Jul; 21(7):519-25. PubMed ID: 12162806
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Development of cell-penetrating peptide-based drug leads to inhibit MDMX:p53 and MDM2:p53 interactions.
    Philippe G; Huang YH; Cheneval O; Lawrence N; Zhang Z; Fairlie DP; Craik DJ; de Araujo AD; Henriques ST
    Biopolymers; 2016 Nov; 106(6):853-863. PubMed ID: 27287767
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Targeting the MDM2/MDM4 interaction interface as a promising approach for p53 reactivation therapy.
    Pellegrino M; Mancini F; Lucà R; Coletti A; Giacchè N; Manni I; Arisi I; Florenzano F; Teveroni E; Buttarelli M; Fici L; Brandi R; Bruno T; Fanciulli M; D'Onofrio M; Piaggio G; Pellicciari R; Pontecorvi A; Marine JC; Macchiarulo A; Moretti F
    Cancer Res; 2015 Nov; 75(21):4560-72. PubMed ID: 26359458
    [TBL] [Abstract][Full Text] [Related]  

  • 50. MDMX: a novel p53-binding protein with some functional properties of MDM2.
    Shvarts A; Steegenga WT; Riteco N; van Laar T; Dekker P; Bazuine M; van Ham RC; van der Houven van Oordt W; Hateboer G; van der Eb AJ; Jochemsen AG
    EMBO J; 1996 Oct; 15(19):5349-57. PubMed ID: 8895579
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Over-expression of the human MDM2 p53 binding domain by fusion to a p53 transactivation peptide.
    Liu Z; Olejniczak ET; Fesik SW
    Protein Expr Purif; 2004 Oct; 37(2):493-8. PubMed ID: 15358376
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Investigating peptide sequence variations for 'double-click' stapled p53 peptides.
    Lau YH; de Andrade P; Sköld N; McKenzie GJ; Venkitaraman AR; Verma C; Lane DP; Spring DR
    Org Biomol Chem; 2014 Jun; 12(24):4074-7. PubMed ID: 24817343
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Conjugation to albumin-binding molecule tags as a strategy to improve both efficacy and pharmacokinetic properties of the complement inhibitor compstatin.
    Huang Y; Reis ES; Knerr PJ; van der Donk WA; Ricklin D; Lambris JD
    ChemMedChem; 2014 Oct; 9(10):2223-6. PubMed ID: 25056114
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Dithiocarbamate-inspired side chain stapling chemistry for peptide drug design.
    Li X; Tolbert WD; Hu HG; Gohain N; Zou Y; Niu F; He WX; Yuan W; Su JC; Pazgier M; Lu W
    Chem Sci; 2019 Feb; 10(5):1522-1530. PubMed ID: 30809370
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Bridged Analogues for p53-Dependent Cancer Therapy Obtained by S-Alkylation.
    Micewicz ED; Sharma S; Waring AJ; Luong HT; McBride WH; Ruchala P
    Int J Pept Res Ther; 2016 Mar; 22(1):67-81. PubMed ID: 26957954
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pseudoesterase activity of albumin: A probable determinant of cholesterol biosynthesis.
    Kumar D; Behal S; Bhattacharyya R; Banerjee D
    Med Hypotheses; 2018 Jun; 115():42-45. PubMed ID: 29685194
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Design of Cyclic Peptides Targeting Protein-Protein Interactions Using AlphaFold.
    Kosugi T; Ohue M
    Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37686057
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Computational Study of Driving Forces in ATSP, PDIQ, and P53 Peptide Binding: C═O···C═O Tetrel Bonding Interactions at Work.
    Lang L; Frontera A; Perez A; Bauzá A
    J Chem Inf Model; 2023 May; 63(10):3018-3029. PubMed ID: 37014944
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Tumor-Targeted Delivery of the p53-Activating Peptide VIP116 with PEG-Stabilized Lipodisks.
    Lundsten S; Hernández VA; Gedda L; Sarén T; Brown CJ; Lane DP; Edwards K; Nestor M
    Nanomaterials (Basel); 2020 Apr; 10(4):. PubMed ID: 32325827
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Molecular Design of Cyclic Peptides with Cell Membrane Permeability and Development of MDMX-p53 Inhibitor.
    Mizuno-Kaneko M; Hashimoto I; Miyahara K; Kochi M; Ohashi N; Tsumura K; Suzuki K; Tamura T
    ACS Med Chem Lett; 2023 Sep; 14(9):1174-1178. PubMed ID: 37736191
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.